Company intelligence / Profile preview
EnGen Bio
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
Overview
EnGen Bio has achieved an important preclinical milestone with its universal Type A influenza vaccine candidate. The company is optimizing a recombinantly manufactured, lyophilized, room temperature-stable subunit vaccine that targets a novel epitope on the flu virus’s M1 matrix protein. This approach aims to elicit long-lasting and broadly neutralizing antibody responses in both humans and animals. No clinical trial results are available yet as programs remain preclinical.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant subunit vaccinesTherapeutic antibodies
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on EnGen Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnGen Bio.